
Get exclusive money-saving offers and guides
Straight to your inbox
Updated
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
TBG Diagnostics Limited is a diagnostics & research business based in Australia. TBG Diagnostics shares (TDL) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. TBG Diagnostics has a trailing 12-month revenue of around $3.7 million..
Our top pick for
US stocks
Our top pick for
Cheap broker fees
Our top pick for
Long-term investing
52-week range | $0.018 - $0.3 |
---|---|
50-day moving average | $0.27 |
200-day moving average | $0.27 |
Target price | N/A |
PE ratio | 67.5 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $0.003 |
Standard brokerage - Australian shares
Competitive broker fees on Australian and international shares
Important: Share trading carries risk of capital loss.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of A$0.27 on 2020-10-22
1 week (2021-01-15) | 0% |
---|---|
1 month (2020-12-23) | 0% |
3 months (2020-10-23) | 0% |
6 months (2020-07-23) | 0% |
1 year (2020-01-23) | 743.75% |
---|---|
2 years (2019-01-19) | N/A |
3 years (2018-01-23) | 321.88% |
5 years (2016-01-19) | N/A |
Valuing TBG Diagnostics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of TBG Diagnostics 's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
TBG Diagnostics 's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 68x. In other words, TBG Diagnostics shares trade at around 68x recent earnings.
That's relatively high compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Revenue TTM | $3.7 million |
---|---|
Gross profit TTM | $2.5 million |
Return on assets TTM | -14.07% |
Return on equity TTM | -69.94% |
Profit margin | -297.27% |
Book value | 0.042 |
Market capitalisation | $58.7 million |
TTM: trailing 12 months
We're not expecting TBG Diagnostics to pay a dividend over the next 12 months.
TBG Diagnostics 's shares were split on 15 May 2007. This wouldn't directly have changed the overall worth of your TBG Diagnostics shares – just the quantity. However, indirectly, the new INF% higher share price could have impacted the market appetite for TBG Diagnostics shares which in turn could have impacted TBG Diagnostics 's share price.
Over the last 12 months, TBG Diagnostics 's shares have ranged in value from as little as $0.018 up to $0.3. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while TBG Diagnostics 's is -15.9028. This would suggest that TBG Diagnostics 's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, TBG Diagnostics has bucked the trend.
TBG Diagnostics Limited, a molecular diagnostics company, develops, manufactures, and markets molecular diagnostics kits, instruments, and services in Taiwan and China. It provides ExProbe HLA and HPA kits for human leukocyte antigen (HLA) and human platelet antigens (HPA) allele genotyping, which uses real time polymerase chain reaction (PCR) techniques with sequence specific primers and probes; Morgan SSP HLA kits for determining HLA alleles using PCR techniques with sequence specific primers; HLAssure SBT HLA Kits for transplantation donor selection; and AccuType SBT analysis software to analyze sequences from all ab1 based files. The company also offers Morgan SSPal HLA Typing Analysis Software, a gel result interpretation software; HLA typing services that offer low to high resolution using PCR fragment analysis (SSP) and DNA sequencing (SBT); QPCR Q6000, a six-channel real time PCR instrument; QzNGS NGS that provides high resolution HLA genotyping; and COVID-19 testing kits. It serves clinical labs, blood centers, and bone marrow registry labs. The company was formerly known as Progen Pharmaceuticals Limited and changed its name to TBG Diagnostics Limited in December 2015. TBG Diagnostics Limited was incorporated in 1989 is based in Greenslopes, Australia.
From the best overall face moisturiser for dry skin to the best body moisturiser, hand moisturiser and tinted moisturiser for dry skin, these are the best 7 moisturisers for dry skin you can buy in Australia right now.
Steps to owning and managing Vanguard Australian Fixed Interest Index ETF units.
Steps to owning and managing Vanguard Ethically Conscious Global Aggregate Bond Index (Hedged) ETF units.
Steps to owning and managing ETFS Morningstar Global Technology ETF units.
Steps to owning and managing BetaShares Global Quality Leaders (Currency Hedged) ETF units.
Steps to owning and managing ETFS ROBO Global Robotics and Automation ETF units.
Steps to owning and managing ETFS FANG+ ETF units.
Steps to owning and managing ETFS S&P Biotech ETF units.
Steps to owning and managing ETFS Reliance India Nifty 50 ETF units.
Steps to owning and managing BetaShares India Quality ETF units.